ATACAND- candesartan cilexetil tablet

Land: Verenigde Staten

Taal: Engels

Bron: NLM (National Library of Medicine)

Werkstoffen:

CANDESARTAN CILEXETIL (UNII: R85M2X0D68) (CANDESARTAN - UNII:S8Q36MD2XX)

Beschikbaar vanaf:

Carilion Materials Management

INN (Algemene Internationale Benaming):

CANDESARTAN CILEXETIL

Samenstelling:

CANDESARTAN CILEXETIL 8 mg

Toedieningsweg:

ORAL

Prescription-type:

PRESCRIPTION DRUG

therapeutische indicaties:

ATACAND is indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous an

Product samenvatting:

Product: 68151-4146 NDC: 68151-4146-3 1 TABLET in a PACKAGE

Autorisatie-status:

New Drug Application

Productkenmerken

ATACAND- CANDESARTAN CILEXETIL TABLET
CARILION MATERIALS MANAGEMENT
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ATACAND SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR ATACAND.
ATACAND (CANDESARTAN CILEXETIL) TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
RECENT MAJOR CHANGES
Warnings and Precautions (5.5) 02/2016
INDICATIONS AND USAGE
ATACAND is an angiotensin II receptor blocker (ARB) indicated for:
•
•
DOSAGE AND ADMINISTRATION
*
STARTING DOSE
TARGET DOSE
Adult Hypertension (2.1)
16 mg tablet once daily
8 – 32 mg tablet total daily dose
Pediatric Hypertension (1 to < 6
years) (2.2)
0.20 mg/kg oral suspension once daily
0.05 – 0.4 mg/kg oral suspension once daily or
consider divided dose
Pediatric Hypertension (6 to < 17
years) (2.2)
< 50 kg 4 – 8 mg tablet once daily
>50 kg 8 – 16 mg tablet once daily
< 50 kg 4 – 16 mg tablet once daily or
consider divided dose
> 50 kg 4 – 32 mg tablet once daily or
consider divided dose
Adult Heart Failure (2.3)
4 mg tablet once daily
32 mg tablet once daily
DOSAGE FORMS AND STRENGTHS
CONTRAINDICATIONS
Known hypersensitivity to product components (4).
Do not co-administer aliskiren with ATACAND in patients with diabetes
(4).
WARNINGS AND PRECAUTIONS
•
•
ADVERSE REACTIONS
•
®
When pregnancy is detected, discontinue ATACAND as soon as possible.
(5.1)
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the developing fetus. (5.1)
Treatment of hypertension in adults and children 1 to < 17 years of
age, to lower blood pressure. Lowering blood
pressure reduces the risk of fatal and non-fatal cardiovascular
events, primarily strokes and myocardial infarctions
(1.1).
Treatment of heart failure (NYHA class II-IV); ATACAND reduces
cardiovascular death and heart failure
hospitalization (1.2).
T he target dose is 32 mg once daily, which is achieved by d